Passage Bio and Remix Therapeutics have announced a definitive merger agreement, creating a combined entity that will operate as Remix Therapeutics. This all-stock transaction will see the new company trade on Nasdaq under the ticker "RMTX". The merger is supported by a concurrent, oversubscribed $100 million private placement, aimed at advancing Remix's pipeline of RNA-modulating therapies.
Strategic Rationale and Financial Backing
In conjunction with the merger, Remix has secured $100 million in a private placement financing round led by Decheng Capital. This substantial capital infusion is expected to fund the combined company's operations well into 2028. The financing provides a clear runway through several key clinical milestones for its lead drug candidate.
Remix Co-Founder and CEO, Dr. Peter Smith, described the transaction as a transformative step for the company's mission to develop a new class of medicines. He emphasized that the strengthened foundation will accelerate the development of RNA-targeted therapies, led by the promising oncology drug REM-422. This move positions the company to translate its science into differentiated treatments for patients with urgent needs.
For Passage Bio, the merger follows a thorough evaluation of strategic alternatives, according to President and CEO Dr. Will Chou. He identified Remix as an ideal partner with a differentiated platform and impactful clinical data for its lead asset. The combination is expected to deliver compelling value and meaningful participation for Passage Bio stockholders in a promising clinical-stage company.
Focus on Lead Candidate REM-422
The combined company's lead program is REM-422, a novel, orally available small molecule designed to degrade MYB mRNA. This drug targets a historically undruggable transcription factor that plays a critical role in the development of multiple cancers. Its unique mechanism involves reprogramming RNA processing to induce the decay of the target mRNA transcript.
REM-422 is currently advancing through Phase 1/2 clinical trials for several indications with high unmet medical need. These studies are evaluating its efficacy in patients with Adenoid Cystic Carcinoma (ACC), a rare salivary gland cancer. Additional trials are underway for Acute Myeloid Leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).
The therapeutic potential of REM-422 has received significant regulatory recognition from the U.S. Food and Drug Administration. The agency has granted the drug Orphan Drug Designation for the treatment of both ACC and AML. Furthermore, it has received Fast Track designation for its development in ACC, which could expedite its review process.
Transaction Details and Future Leadership
Under the terms of the agreement, pre-merger Passage Bio shareholders are expected to own approximately 7% of the new entity. The remaining 93% will be held by pre-merger Remix stockholders, including investors from the concurrent financing round. This ownership structure is subject to adjustment based on Passage Bio's net cash at closing.
As part of the transaction, Passage Bio shareholders will receive a non-transferable Contingent Value Right (CVR). This CVR entitles them to a pro rata share of any net proceeds from milestones related to Passage Bio's out-licensed pediatric gene therapy assets. The potential for any payment from these CVRs is not guaranteed.
The leadership of the combined company will be composed of the current Remix Therapeutics team. Dr. Peter Smith will continue as CEO, while Matthew Patterson will serve as the chairman of the Board of Directors. Peter Colabuono of Decheng Capital is also set to join the board upon the transaction's completion.
This strategic merger and concurrent financing position the new Remix Therapeutics as a formidable player in the RNA therapeutics space. With a robust financial runway extending into 2028, the company is poised to advance its lead candidate, REM-422, through pivotal clinical trials. The transaction, pending stockholder and regulatory approvals, is anticipated to close in the fourth quarter of 2026.